Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy
Covered in this story
Analyst targets on Thermo Fisher Scientific
- Morgan Stanley: $560 → $650 by Jul 2027 · Overweight via GuruFocus
- RBC Capital Markets: $568 → $580 by Jul 2027 via GuruFocus
- Barclays: $568 → $650 by Jul 2027 · Overweight via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $TMO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Thermo Fisher Scientific →Dalsna Finance is currently tracking 49 stories mentioning Thermo Fisher Scientific, the earliest published 23 Jul 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.